Pharmaceuticals
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
HIGHLIGHTS * Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity's67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical re...
2023-11-30 21:59
2241
111, Inc. Announces Third Quarter 2023 Unaudited Financial Results
SHANGHAI, Nov. 30, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the third quart...
2023-11-30 14:00
4638
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort
HIGHLIGHTS * Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67 Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled and treated 3 participants who received therapy with67Cu-SAR-bisPSMA at the highest dose level of 12GBq. * No dose limiting toxicit...
2023-11-29 21:58
2125
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that its Dry Eye Disease (DED) therape...
2023-11-29 21:00
4190
Dr. Liu Jian, President of Medicilon Drug Discovery Division, wins the Thomas Alva Edison Patent Award
BOSTON, Nov. 28, 2023 /PRNewswire/ -- Dr. Liu Jian, President of the Drug Discovery Division at Medicilon, has been awarded the Thomas Alva Edison Patent Award for 2023 from the New Jersey Research and Development Committee. This recognition stems from his innovative patent on the PCSK9 inhibitor...
2023-11-28 21:30
1955
Akeso Launches Construction of Shanghai Global R&D Center to Accelerate Its Innovation Globalization Strategy
HONG KONG, Nov. 28, 2023 /PRNewswire/ -- The groundbreaking ceremony for Akeso (9926.HK) Shanghai Global R&D Center was successfully held at the Zhangjiang headquarters park inShanghai. The establishment of the Akeso Global R&D Center signifies a crucial step in Akeso's innovative globalization ...
2023-11-28 21:00
2772
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients
HONG KONG, Nov. 27, 2023 /PRNewswire/ -- Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso's PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/- bevacizumab, has met one of its primary endpoints of progression-fre...
2023-11-27 21:30
2265
Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication
SUZHOU, China, and ROCKVILLE, Md., Nov. 24, 2023 /PRNewswire/ -- 23 Nov, 2023, on the second anniversary of the initial approval for olverembatinib, Ascentage Pharma hosted a ceremony in Suzhou,China, marking the launch of olverembatinib in a newly approved indication and the dispatch of the firs...
2023-11-24 19:57
2702
China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation
SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) ofChina has accepted the...
2023-11-24 19:00
2607
PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome
* Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a. Clarkson Disease) and vessel-related rare disease indications * Unique Tie2-activating antibody program, PMC-403, demonstrates efficacy in improving survival and reducing vascular leak...
2023-11-23 10:31
2396
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
* By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale * This end-to-end continuous bioprocess, which is in place for WuXi Biologics global manufacturing network, is...
2023-11-22 13:21
4436
ST Pharm Presented '100-Day Expedite Strategy', Preparedness and Proactive Measures for Future Pandemic at Korea-CEPI R&D Workshop
SEOUL, South Korea, Nov. 20, 2023 /PRNewswire/ -- Nov. 21, 2023 local time, ST Pharm announced 'Rapid Preparedness of Pandemic Vaccine in 100 Days using ST Pharm's own mRNA Platform Technology' at the Korea-CEPI R&D Workshop in World Bio Summit 2023, organized by Korea Health Industry Development...
2023-11-21 12:00
2122
Porton Advanced and Ascle Therapeutics Reached a Strategic Partnership to Promote the Application of NK Cells in Cancer Prevention, Beauty, and Anti-aging
SUZHOU, China, Nov. 20, 2023 /PRNewswire/ -- On November 20, 2023, Porton Advanced announced a strategic partnership with Ascle Therapeutics to jointly develop and produce NK cells, assist in the development and innovation in gene and cell therapy, and accelerate the application of NK cells in ca...
2023-11-20 20:00
1606
First Subject Enrolled in Phase 1 Study of MRX-5
SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as ＂MicuRx＂) announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial inAustralia. MRX-5 is a new type of benzodiazepine...
2023-11-20 18:34
1930
Sanyou's "STAL Platform" is a significant advancement in the field of drug discovery.
SHANGHAI, Nov. 17, 2023 /PRNewswire/ -- Sanyou's "STAL Innovative Biologics Drug Discovery Platform" is a significant advancement in the field of drug discovery. This cutting-edge platform enables the screening of thousands of innovative lead molecules against a common target, surpassing the capa...
2023-11-18 08:00
3424
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
Conference call webcast is scheduled for November 22 at 9 a.m. ET.
SINGAPORE, Nov. 17, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
2023-11-17 22:21
4307
Taiwan Lubricate for academic research and health products development
TAICHUNG, Nov. 17, 2023 /PRNewswire/ -- Based in Taiwan, T-BAL is the leading service provider in measurements of lipids and metabolites for both academics and industry. In the collaboration with Lipotype GmbH,Germany (the world leader in lipidomics profiling service), T-BAL has developed advance...
2023-11-17 20:00
1569
epitoMAP Inc., Animal Allergy Clinical Laboratories Inc. and Nippon Zenyaku Kogyo Co., Ltd. Enter into License Agreement
SAGAMIHARA, Japan, Nov. 17, 2023 /PRNewswire/ -- epitoMAP Inc. (hereinafter "epitoMAP") and Animal Allergy Clinical Laboratories Inc. (hereinafter "AACL") entered into a License Agreement for an antibody pharmaceutical for veterinary use, CRE-DR-B, with Nippon Zenyaku Kogyo Co., Ltd. (hereinafter...
2023-11-17 16:00
1905
WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange
HONG KONG, Nov. 17, 2023 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization ("CRDMO") focused on antibody drug conjugates ("ADC") and the broader bioconjugate market, listed on the...
2023-11-17 14:00
3727
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial
SHANGHAI, Nov. 16, 2023 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, is pleased to announce the topline results from the ACcomplisH China Phase 2 Trial in children with achondroplasia (ACH) aged 2 to 10 years. In the trial, ...
2023-11-16 22:00
2065
Week's Top Stories
Most Reposted
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 322 media titles]
2026-02-02 10:00
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 322 media titles]
2026-01-29 15:06
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 312 media titles]
2026-02-03 11:00
Mastercard Launches Portfolio of Fleet Solutions in Asia Pacific
[Picked up by 308 media titles]
2026-02-04 09:00Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 303 media titles]
2026-02-03 12:00